RELB anticorps (AA 400-579)

N° du produit ABIN7172594

Détail du produit anti-RELB anticorps

Antigène: RELB (V-Rel Reticuloendotheliosis Viral Oncogene Homolog B (RELB))

Épitope: AA 400-579

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp RELB est non-conjugé

Application: Western Blotting (WB), ELISA, Immunofluorescence (IF)

Réactivité croisée: Humain, Souris

Purification: >95%, Protein G purified

Immunogène: Recombinant Human Transcription factor RelB protein (400-579AA)

Isotype: IgG

Information d'application

Indications d'application: Recommended dilution: WB:1:2000-1:10000, IF:1:50-1:500,

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C,-80 °C

Stockage commentaire: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Détails sur RELB

Antigène: RELB (V-Rel Reticuloendotheliosis Viral Oncogene Homolog B (RELB))

Autre désignation: RELB (RELB Produits)

Synonymes: anticorps shep, anticorps I-REL, anticorps IREL, anticorps REL-B, anticorps XRelB, anticorps relb-A, anticorps GC-rich, anticorps avian reticuloendotheliosis viral (v-rel) oncogene related B, anticorps RELB proto-oncogene, NF-kB subunit, anticorps v-rel avian reticuloendotheliosis viral oncogene homolog B S homeolog, anticorps Relb, anticorps RELB, anticorps relb.S

Sujet:

Background: NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49. As a member of the NUPR1/RELB/IER3 survival pathway, may provide pancreatic ductal adenocarcinoma with remarkable resistance to cell stress, such as starvation or gemcitabine treatment. Regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-ARNTL/BMAL1 heterodimer in a CRY1/CRY2 independent manner. Increased repression of the heterodimer is seen in the presence of NFKB2/p52.

Aliases: I REL antibody, I-Rel antibody, IREL antibody, Nuclear factor of kappa light polypeptide gene enhancer in B cells 3 antibody, relB antibody, RELB_HUMAN antibody, Reticuloendotheliosis viral oncogene homolog B antibody, Transcription factor Rel B antibody, Transcription factor RelB antibody, v rel avian reticuloendotheliosis viral oncogene homolog B antibody, v rel reticuloendotheliosis viral oncogene homolog B antibody

UniProt: Q01201

Pathways: Signalisation NF-kappaB, Signalisation RTK